Donor Specific HLA Alloantibodies in Liver Transplantation

Active, not recruitingOBSERVATIONAL
Enrollment

858

Participants

Timeline

Start Date

August 15, 2015

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Complication of Transplanted Liver
Interventions
OTHER

HLA-alloantibodies exposure

"Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)"

Trial Locations (5)

2100

Department of Surgical Gastroenterology and Transplantation, Rigshospitalet - Copenhagen University Hospital, Copenhagen

14186

Division of Transplantation Surgery, Karolinska Institutet, Stockholm

PL 372, 00029 HUS

Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki

0424

Department of Transplantation Medicine, Oslo University Hospital, Oslo

413 45

Surgery Department, Transplantation and Liver Surgery Unit, Sahlgrenska University Hospital, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Helsinki University Central Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT02784080 - Donor Specific HLA Alloantibodies in Liver Transplantation | Biotech Hunter | Biotech Hunter